Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD )

4.275 -0.155 (-3.50%)
Streaming Delayed Price Updated: 1:57 PM EST, Jan 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ironwood Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >
Ironwood Pharmaceuticals: Q3 Earnings Insights
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional... 
Via Benzinga
Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation. 
Via Benzinga
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Wells Fargo Maintains Equal-Weight Rating for Ironwood Pharmaceuticals: Here's What You Need To Know
  Wells Fargo has decided to maintain its Equal-Weight rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) and raise its price target from $12.00 to $13.00. Shares of Ironwood Pharmaceuticals are trading... 
Via Benzinga
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
5 Value Stocks In The Healthcare Sector
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals: Q1 Earnings Insights
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Ironwood Pharmaceuticals Q1 2022 Earnings Conference Call On May 5, 2022 At 08:30 AM ET
Ironwood Pharmaceuticals (NASDAQ:IRWD) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 22, 2022
Upgrades 
Via Benzinga
Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Jefferies Raises Price Target On This Small-Cap 'Stand Out' Biotech Stock
Ardelyx Inc (NASDAQ: ARDX) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1. Analyst... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples... 
Via Benzinga
Ironwood Pharmaceuticals Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data Ironwood Pharmaceuticals (NASDAQ:IRWD) posted a 25.91% decrease in earnings from Q3. Sales, however, increased by 12.9% over the previous quarter to $117.13 million. 
Via Benzinga
Ironwood Reports Mixed Q4 Results; Linzess Joins Blockbuster Club As US Sales Exceed $1B
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) reported Q4 FY21 sales of $117.1 million, compared to $116.7 million in Q4 FY20, beating the consensus of $109.87 million.... 
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
Recap: Ironwood Pharmaceuticals Q4 Earnings
  Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q4 earnings results on Thursday, February 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
Earnings Outlook For Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ:IRWD) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.